Who is Smart Enough to Decide how to Improve the Human Species?
By Joel Achenbach,
The Washington Post
| 01. 05. 2016
Untitled Document
Which technology promises to most dramatically change our lives? A plausible answer is artificial intelligence -- see part 2 of our series "The Resistance." But a lot of smart people would say biotechnology. Or maybe both, in a glorious scientific tango.
Genetic engineering and molecular biology benefit from the processing power creating by the digital revolution. There's a convergence happening -- and this is arguably one of the biggest stories in the world right now.
Not long ago I walked around Kendall Square with Juan Enriquez. He’s an academic, investor and co-author of “Evolving Ourselves: How Unnatural Selection and Nonrandom Mutation Are Changing Life on Earth." The book's premise: We’re undergoing directed evolution. Darwinian natural selection is giving way to bio-engineering, both the conscious kind in the laboratory and as an unintended consequence of urbanization, changes in lifestyle, the domestication of animals and so on. There's a reason obesity, autism, asthma and other auto-immune diseases are on the rise; these are side-effects of how we are evolving in our modern environment.
As Enriquez and co-author Steve Gullans write...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...